Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.
Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, Ikegami T, Fujii H, Toyoda H, Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanoue T, Nakajima A, Takahashi H; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Oeda S, et al. Among authors: morishita a. Hepatol Res. 2023 Jun;53(6):489-496. doi: 10.1111/hepr.13890. Epub 2023 Mar 7. Hepatol Res. 2023. PMID: 36807720
Correlation between serum galectin-9 levels and liver fibrosis.
Fujita K, Niki T, Nomura T, Oura K, Tadokoro T, Sakamoto T, Tani J, Yoneyama H, Morishita A, Kuroda N, Arai T, Nishimoto N, Himoto T, Hirashima M, Masaki T. Fujita K, et al. Among authors: morishita a. J Gastroenterol Hepatol. 2018 Feb;33(2):492-499. doi: 10.1111/jgh.13851. J Gastroenterol Hepatol. 2018. PMID: 28618039
Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T. Toyoda H, et al. Among authors: morishita a. J Gastroenterol Hepatol. 2020 May;35(5):855-861. doi: 10.1111/jgh.14874. Epub 2019 Nov 19. J Gastroenterol Hepatol. 2020. PMID: 31609495 Clinical Trial.
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.
Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T. Toyoda H, et al. Among authors: morishita a. J Gastroenterol Hepatol. 2020 Aug;35(8):1420-1425. doi: 10.1111/jgh.14982. Epub 2020 Jan 31. J Gastroenterol Hepatol. 2020. PMID: 31950525
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group. Nozaki A, et al. Among authors: morishita a. Hepatol Int. 2020 Mar;14(2):225-238. doi: 10.1007/s12072-020-10019-z. Epub 2020 Mar 3. Hepatol Int. 2020. PMID: 32128704
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Sumida Y, et al. Among authors: morishita a. Int J Mol Sci. 2020 Jul 13;21(14):4939. doi: 10.3390/ijms21144939. Int J Mol Sci. 2020. PMID: 32668632 Free PMC article. Review.
391 results